RapidEx SIGNED
Validation of a point-of-care H-FABP test for a rapid exclusion of Acute Myocardial Infarction in patients with cardiac complaints.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RapidEx project word cloud
Explore the words cloud of the RapidEx project. It provides you a very rough idea of what is the project "RapidEx" about.
Project "RapidEx" data sheet
The following table provides information about the project.
| Coordinator |
FABPULOUS BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Project website | http://fabpulous.com/ |
| Total cost | 1˙633˙750 € |
| EC max contribution | 1˙633˙750 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2014 |
| Funding Scheme | SME-2 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-04-01 to 2017-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FABPULOUS BV | NL (MAASTRICHT) | coordinator | 1˙633˙750.00 |
Map
Project objective
There is a pressing need for improvement of the diagnosis of acute myocardial infarction (AMI) for healthcare professionals (HCP). 1–1,5% of the population consult a physician each year with chest pain complaints. While the majority (60–80%) of these patients are sent to a hospital for further inspection, eventually AMI is diagnosed in only 8–18% of these cases. Consequently, a rapid, objective test that helps to better select patients suspected of AMI by HCPs would reduce the number of unnecessary hospital referrals and admissions, thereby saving costs and contributing to a more sustainable healthcare.
FABPulous (SME) is a medical device company spun out of Maastricht University in 2008. The core of the company is its innovative proprietary technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages over current technologies in point-of-care and home testing.
The CE-marked H-FABP True Rapid Test (H-FABP TRT) developed by FABPulous aids the HCP in ruling out AMI with a very high level of confidence. It is based on the heart-type fatty acid binding protein (H-FABP), which can be used as biomarker for AMI. With H-FABP TRT a physician is able to rule out the occurrence of an AMI for a large proportion of patients suspected of AMI. It is intended for use in both primary and emergency care.
In this project FABPulous seeks to medico-economically validate H-FABP TRT in primary (NetherlandsBelgium) and emergency care (UK) by performing two clinical trials. Outcomes of these studies lead to adoption of H-FABP TRT in medical guidelines and form the basis of a request for reimbursement towards health insurers. In this project FABPulous will improve the production process as well in order to decrease the cost price to €5 per test.
The addressable market in NW Europe alone amounts to at least 2 mln tests. The phased introduction plan leads to €8.6 mln revenue with a gross margin of €6.5 mln in 2018.
Deliverables
| Clinical study protocol emergency care trial | Documents, reports | 2019-04-15 17:08:30 |
Take a look to the deliverables list in detail: detailed list of RapidEx deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RAPIDEX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RAPIDEX" are provided by the European Opendata Portal: CORDIS opendata.